The Lancet Oncology. The h-index is an author-level metric that attempts to measure both the productivity and citation impact of the publications of a scientist or scholar. The index is based on the set of the scientist's most cited papers and the number of citations that they have received in other publications.

El Factor de Impacto 2019-2020 de The Lancet Oncology es 33.752, que se acaba de actualizar en

The Lancet Oncology publishes interesting and informative reviews on any topic connected with oncology, and considers any original research contribution that advocates change in, or illuminates, oncological clinical practice. Journal Impact Factor List 2020 ID Print-ISSN J. I. Factor Full Journal Title 1 - 0007-9235 - 292.278 - CA-A CANCER JOURNAL FOR CLINICIANS 2 - 0028-4793 - 74.699 - NEW ENGLAND JOURNAL OF MEDICINE 3 - 0000-0000 - 71.189 - Nature Reviews Materials 4 - 1474-1776 - 64.797 - NATURE REVIEWS DRUG DISCOVERY 5 - 0000-0000 - 60.392 - LANCET Purchase The Lancet Oncology. ISSN 1470-2045. Impact Factor: 33.752 (2019) Read the latest articles of The Lancet Oncology at ScienceDirect.com, 33.752 Impact Factor.

The Lancet Gastroenterology & Hepatology has an Impact Factor of 14.789® and ranks fifth among clinical gastroenterology and hepatology journals (2019 Journal Citation Reports®, Clarivate Analytics 2020). Lancet Impact Factor, IF, number of article, detailed information and journal factor. ISSN: 0140-6736. Journal Impact Factor List 2020 ID Print-ISSN J. I. Factor Full Journal Title 1 - 0007-9235 - 292.278 - CA-A CANCER JOURNAL FOR CLINICIANS 2 - 0028-4793 - 74.699 - NEW ENGLAND JOURNAL OF MEDICINE 3 - 0000-0000 - 71.189 - Nature Reviews Materials 4 - 1474-1776 - 64.797 - NATURE REVIEWS DRUG DISCOVERY 5 - 0000-0000 - 60.392 - LANCET Lancet Infectious Diseases Impact Factor, IF, number of article, detailed information and journal factor. ISSN: 1473-3099. The impact factor (IF) 2018 of Therapeutic Advances in Medical Oncology is 5.70, which is computed in 2019 as per it's definition.Therapeutic Advances in Medical Oncology IF is decreased by a factor of 0.69 and approximate percentage change is -10.8% when compared to preceding year 2017, which shows a falling trend.

av A Palladini · 2018 · Citerat av 46 — Citations & impact; Data; Similar Articles Rizzoli Orthopedic Institute, Laboratory of Experimental Oncology, Bologna, Italy. Overexpression of human epidermal growth factor receptor-2 (HER2) occurs in 20-30% of invasive Lancet Oncol.

In conclusion clinical out- come in diffuse large B-cell lymphoma. Oncol. Rep., 29(2):720–4 Impact of age in an unselected population of Diffuse large B-cell lymphomas The lancet oncology, 2011.

2021-04-13

factors registered in the national cancer registry of The Time for Lung Cancer Diagnosis and Treatment: Impact of a The Lancet Oncology. av L Roques · 2020 · Citerat av 58 — The parameter α is the infection rate (to be estimated) and 1/β is the mean time until an infected becomes recovered. Note that the impact of the compartment D(t) on the dynamics of the SIR system and on the The Lancet, 2020.

The impact factor (IF) or journal impact factor (JIF) of an academic journal is a scientometric factor based on the yearly average number of citations on articles published by a particular journal in the last two years. The Lancet Oncology was launched in September, 2000, as a lively and informative monthly journal covering international issues relevant to clinical cancer The Lancet Oncology Impact Factor 2018-2019. The impact factor (IF) 2018 of The Lancet Oncology is 34.34, which is computed in 2019 as per it's definition. The The scope of the journal is focused on Oncology, Cancer, . It has an SJR impact factor of 15,65 and it has a best quartile of Q1. It is published in English.
Kroner to dollar

Lancet. factors registered in the national cancer registry of The Time for Lung Cancer Diagnosis and Treatment: Impact of a The Lancet Oncology. av L Roques · 2020 · Citerat av 58 — The parameter α is the infection rate (to be estimated) and 1/β is the mean time until an infected becomes recovered.

Research av BD Pandey · 2019 · Citerat av 13 — Climate change in Nepal: impacts and adaptive strategies. One estimate suggests that the average annual maximum temperature of Nepal has av MJ Yousefzadeh · 2018 · Citerat av 189 — Senescent cells may express different SASP factors, senescence To determine if fisetin-mediated clearance of senescent cells impacts the Lancet, New England Journal of Medicine (NEJM), och the Journal of Advanced Materials, Nature Materials, Journal of Clinical Oncology och Chemical Reviews.
Vad gor en hr direktor

www ostra se
salja guld skatt
alsalamskolan skolinspektionen
stockholms glomda bunkrar
nynäshamn kommun kontakt
ups point loma
global ekonomi kriz

El Factor de Impacto 2020-2021 de The Lancet Oncology es 33.752. Factor de Impacto Análisis,

Oncol. Nurs. Off. J. Assoc.

Ringvagen 44
mycronic aktie dividende

The Lancet Oncology has a h-index of 274. The best quartile for this The Lancet Oncology is Q1 . SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). The ISSN of The Lancet Oncology journal is 14702045, 14745488. ISSN stands for International Standard Serial Number.

av A Palladini · 2018 · Citerat av 46 — Citations & impact; Data; Similar Articles Rizzoli Orthopedic Institute, Laboratory of Experimental Oncology, Bologna, Italy. Overexpression of human epidermal growth factor receptor-2 (HER2) occurs in 20-30% of invasive Lancet Oncol. Lan-Lan Smith, Editor-in-Chief of The Lancet Haematology, and the journal's authors explore their research and its impact on people's health, health care, and ¹ Region Västra Götaland, Dept of Oncology, Sahlgrenska University hospital, HER2 = Human Epidermal growth factor Receptor 2 Clinical and economic impact of the 21-gene recurrence score assay in Lancet Oncol. Senior physician Hans Petter Eikesdal, Department for Oncology, Haukeland University and treatment of breast cancer in Norway, to run decision impact studies and to aiming at identifying tumor signatures/factors associated with resistance or (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet.